SOM Biotech
Phase 3We are a cutting-edge, late-stage clinical development company pioneering an Artificial Intelligence (AI) platform for drug discovery since 2010 dedicated to rare CNS disorders.
Founded
2010
Focus
Small Molecules
About
We are a cutting-edge, late-stage clinical development company pioneering an Artificial Intelligence (AI) platform for drug discovery since 2010 dedicated to rare CNS disorders.
Funding History
3Total raised: $13M
Grant$3MEuropean CommissionJun 15, 2020
Series A$8MCaixa Capital RiscJun 15, 2018
Seed$2MUndisclosedJun 15, 2015
Company Info
TypePrivate
Founded2010
LocationBarcelona, Spain
StagePhase 3
Contact
SIMILAR COMPANIES
A4Cell
Pre-clinical · Barcelona
Ability Pharma
Phase 2 · Barcelona
Abyntek Biopharma
Pre-clinical · Derio
Acellera
Pre-clinical · Barcelona
BeCytes Biotechnologies
Pre-clinical · Barcelona
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile